Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium

Autor: Koenraad Norga, Susanne Schmidt, Bénédicte Brichard, Anne Uyttebroeck, Barbara De Moerloose, Caroline Piette, Alina Ferster, Tim Lammens, N. Francotte, Jutte van der Werff ten Bosch, Veerle Mondelaers, Yves Benoit, Charlotte Verbeke, Katrien Vandemeulebroecke
Přispěvatelé: UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Clinical sciences, Growth and Development, Pediatrics
Rok vydání: 2019
Předmět:
Male
Allergy
acute lymphoblastic leukaemia
Erwinia
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
Belgium
Prospective Studies
Child
media_common
biology
medicine.diagnostic_test
Lymphoma
Non-Hodgkin
Hematology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
030220 oncology & carcinogenesis
Child
Preschool
Female
Antibody
medicine.drug
Drug
medicine.medical_specialty
Asparaginase
Adolescent
media_common.quotation_subject
therapeutic drug monitoring
03 medical and health sciences
silent inactivation
Internal medicine
medicine
Escherichia coli
Humans
Pediatrics
Perinatology
and Child Health
Dexamethasone
childhood
business.industry
Infant
medicine.disease
biology.organism_classification
allergy
asparaginase
Lymphoma
chemistry
Therapeutic drug monitoring
biology.protein
Human medicine
business
030215 immunology
Hématologie
Zdroj: British journal of haematology
British journal of haematology, Vol. 190, no. 1, p. 105-114 (2020)
ISSN: 1365-2141
0007-1048
Popis: Asparaginase (ASNase) is an important anti-leukaemic drug in the treatment of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL). A substantial proportion of patients develop hypersensitivity reactions with anti-ASNase neutralising antibodies, resulting in allergic reactions or silent inactivation (SI), and characterised by inactivation and rapid clearance of ASNase. We report results of a prospective, real-time therapeutic drug monitoring of pegylated Escherichia coli (PEG-)ASNase and Erwinia ASNase in children treated for ALL and NHL in Belgium. Erwinia ASNase was given as second-line after hypersensitivity to PEG-ASNase. In total, 286 children were enrolled in the PEG-ASNase cohort. Allergy was seen in 11¸2% and SI in 5·2% of patients. Of the 42 patients treated with Erwinia ASNase, 7·1% experienced allergy and 2·4% SI. The median trough PEG-ASNase activity was high in all patients without hypersensitivity. After Erwinia administration significantly more day 3 samples had activities
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: